ClinicalTrials.gg
RecruitingNCT07531693PROSPERUpdated Nov 6, 2026

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

An observational study in HR+/HER2- Early Breast Cancer, sponsored by Institut fuer Frauengesundheit. Recruiting at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Institut fuer Frauengesundheit · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 6, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit — 5 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut fuer Frauengesundheit.

Started
2026
with 1 other
Observational
2 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 9th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Breast Neoplasms by Institut fuer Frauengesundheit, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

03

Conditions studied

  • HR+/HER2- Early Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be selected from up to 30 study sites across Germay. Sites will be selected from certified breast cancer centers that have experience providing adjuvant treatment to breast cancer patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Femal patients age 18 or older at time of
  • Confirmed diagnosis of HR+/- early breast cancer (no distant )
  • Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)
  • Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025

Exclusion criteria

Exclusion Criteria:

  • Locally advanced or breast cancer
  • Male patients
  • Patients with (s) for abemaciclib therapy according to SmPC
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • High-risk HR+/HER2- early breast cancer patients

    High-risk HR+/HER2- early breast cancer patients under abemaciclib therapy

This study also gives AbemaciclibStudies of AbemaciclibAbemaciclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Abemaciclib persistence rate

    Abemaciclib persistence rate (defined as ongoing abemaciclib therapy)

    Time frame: 6 months after therapy start

07

Study locations

1 of 1 sites recruiting
  • Department of Obstetrics and Gynaecology, Uniklinikum Erlangen
    Erlangen, Bavaria 91054, Germany
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2026 → Jan 2027 and completion Mar 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 15, 2026
StartActual
Feb 19, 2026
Primary completionEst.
Jan 2027was Sep 2026
CompletionEst.
Jun 2027was Mar 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jan 2027
Nov 6, 2026
Study completion
Mar 2027→Jun 2027
Nov 6, 2026
Contact
Study contact's phone or email changed: •••6438→•••0613; s•••@ifg-erlangen.de→p•••@ifg-erlangen.de. See the current contact
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Sep 2026→Jan 2027
    Study completion Mar 2027→Jun 2027
    Contact Study contact's phone or email changed: •••6438→•••0613; s•••@ifg-erlangen.de→p•••@ifg-erlangen.de. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07531693
Lead sponsor
Institut fuer Frauengesundheit
Collaborators
Lilly Deutschland GmbH Germany, AGO-B Breast Study Group
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Feb 19, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Sponsor's study office
Contact
prosper@ifg-erlangen.de
+49 9131 91880613
Peter A. Fasching, Prof. Dr. med.
study chair · Department of Obstetrics and Gynaecology, Uniklinikum Erlangen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion